Breast Thermography is a Noninvasive Prognostic Procedure that Predicts Tumor Growth Rate in Breast Cancer Patients
Ann N Y Acad Sci. 1993 Nov 30;698:153-8.
Breast thermography is a noninvasive prognostic procedure that predicts tumor growth rate in breast cancer patients.
Elliott Mastology Center, Baton Rouge, Louisiana 70816.
Our recent retrospective analysis of the clinical records of patients who had breast thermography demonstrated that an abnormal thermogram was associated with an increased risk of breast cancer and a poorer prognosis for the breast cancer patient. This study included 100 normal patients, 100 living cancer patients, and 126 deceased cancer patients. Abnormal thermograms included asymmetric focal hot spots, areolar and periareolar heat, diffuse global heat, vessel discrepancy, or thermographic edge sign. Incidence and prognosis were directly related to thermographic results: only 28% of the noncancer patients had an abnormal thermogram, compared to 65% of living cancer patients and 88% of deceased cancer patients. Further studies were undertaken to determine if thermography is an independent prognostic indicator. Comparison to the components of the TNM classification system showed that only clinical size was significantly larger (p = 0.006) in patients with abnormal thermograms. Age, menopausal status, and location of tumor (left or right breast) were not related to thermographic results. Progesterone and estrogen receptor status was determined by both the cytosol-DCC and immunocytochemical methods, and neither receptor status showed any clear relationship to the thermographic results. Prognostic indicators that are known to be related to tumor growth rate were then compared to thermographic results. The concentration of ferritin in the tumor was significantly higher (p = 0.021) in tumors from patients with abnormal thermograms (1512 +/- 2027, n = 50) compared to tumors from patients with normal thermograms (762 +/- 620, n = 21). Both the proportion of cells in DNA synthesis (S-phase) and proliferating (S-phase plus G2M-phase, proliferative index) were significantly higher in patients with abnormal thermograms. The expression of the proliferation-associated tumor antigen Ki-67 was also associated with an abnormal thermogram. The strong relationships of thermographic results with these three growth rate-related prognostic indicators suggest that breast cancer patients with abnormal thermograms have faster-growing tumors that are more likely to have metastasized and to recur with a shorter disease-free interval.
The benefits of DITI do vary between age and risk groups.
With the pre mammogram age group (under 50) the benefits of screening to detect any findings or changes that justify additional testing or closer monitoring are simple. With any positive DITI findings in this younger age group, any mammogram and ultrasound sensitivity and specificity will be increased with the objective DITI findings targeting a dysfunction and location and providing decision making information in women that would not have otherwise been tested.
It takes years for most cancers to develop to the stage that they can be detected with mammogram or ultrasound (dense enough for location and biopsy) so DITI is ideally placed as a screening tool to identify changes over time in the ‘early’ development stages, before there is more advanced pathology that can be detected with other tests.
The major benefit in this group is in detecting early changes that precede malignant pathology that will become diagnosable at some stage.
Early detection is aimed at prevention and if early changes are detected then we have an opportunity to intervene and change the outcome.
The earlier an abnormality is detected the better the treatment options will be, resulting in a better outcome.
Prevention may include treatment of inflammation, fibrocystic disease, lymph congestion, estrogen dominance and more specific conditions like angiogenesis. [Read More…]
Thermograms vs. mammograms
Published: October 5, 2010
Taking the sane approach for better breast health.
TODAY, MANY WOMEN with a family history of breast cancer are opting for genetic testing to determine whether they carry the abnormal breast cancer genes one (BRCA1) or two (BRC2). When the BRCA1 and BRCA2 genes are healthy, the body is more likely to hinder breast cancer cell growth. When these same women test positive for the (mutated) breast cancer gene, many are opting for a preventative bilateral mastectomy (the removal of two, usually healthy, breasts). This is happening more and more, even though only five to ten percent of all new breast cancers occur in women who carry the gene!1
Women wrongly conclude that if they carry these mutated genes, they are destined to develop cancer. Dr. Colin Begg, Chair of the Department of Epidemiology and Biostatistics at Memorial Sloan-Kettering Cancer Center, and fellow researchers determined after studying 2000 women from different countries that breast cancer risk varies widely among women with mutated BRCA1 and BRCA2 genes. Other factors contribute to a women’s risk, including family history, diet, and lifestyle choices.2 This means that testing positive doesn’t mean you will get breast cancer—and testing negative doesn’t mean you are protected from developing breast cancer! [Read More…]
FOX 10’s Laura Sambol introduces us to Digital Thermography, but we do want to let you know, that there are some medical images that may not be for everyone in the family.